Promoter Hypomethylation and Expression Is Conserved in Mouse Chronic Lymphocytic Leukemia Induced by Decreased or Inactivated Dnmt3a

Cell Reports

Volumn 15, Issue 6, 2016, Pages 1190-1201

  Haney, Staci L ^a   Upchurch, G Michael ^b   Opavska, Jana ^b   Klinkebiel, David ^a   Hlady, Ryan A ^c   Suresh, Abhinav ^b   Pirruccello, Samuel J ^a,b   Shukla, Vipul ^a   Lu, Runqing ^a   Costinean, Stefan ^a   Rizzino, Angie ^a,b   Karpf, Adam R ^b   Joshi, Shantaram ^a,b   Swanson, Patrick ^d   Opavsky, Rene ^a,b  

^a UNIVERSITY OF NEBRASKA MEDICAL CENTER   (United States)

^b UNIVERSITY OF NEBRASKA MEDICAL CENTER   (United States)

^c MAYO GRADUATE SCHOOL   (United States)

^d CREIGHTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DNA METHYLTRANSFERASE 3A; DNA (CYTOSINE 5) METHYLTRANSFERASE; TRANSCRIPTOME;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CARCINOGENICITY; CHRONIC LYMPHATIC LEUKEMIA; CONTROLLED STUDY; DNA METHYLATION; GENE EXPRESSION; GENE LOCUS; GENE LOSS; GENE OVEREXPRESSION; HAPLOINSUFFICIENCY; LEUKEMOGENESIS; MOUSE; MYELOPROLIFERATIVE DISORDER; NONHUMAN; PRIORITY JOURNAL; PROMOTER REGION; TUMOR SUPPRESSOR GENE; ANIMAL; CELL PROLIFERATION; DEFICIENCY; ENZYMOLOGY; GENE EXPRESSION REGULATION; GENETIC TRANSCRIPTION; GENETICS; HETEROZYGOTE; HUMAN; METABOLISM;

ANIMALS; CELL PROLIFERATION; DNA (CYTOSINE-5-)-METHYLTRANSFERASE; DNA METHYLATION; GENE EXPRESSION REGULATION, LEUKEMIC; HETEROZYGOTE; HUMANS; LEUKEMIA, LYMPHOCYTIC, CHRONIC, B-CELL; MICE; PROMOTER REGIONS, GENETIC; TRANSCRIPTION, GENETIC; TRANSCRIPTOME;

EID: 84964635596     PISSN: None     EISSN: 22111247     Source Type: Journal    
DOI: 10.1016/j.celrep.2016.04.004     Document Type: Article

References (34)

1. Beck-Engeser G.B., Lum A.M., Huppi K., Caplen N.J., Wang B.B., Wabl M. Pvt1-encoded microRNAs in oncogenesis. Retrovirology 2008, 5:4.
2. Celik H., Mallaney C., Kothari A., Ostrander E.L., Eultgen E., Martens A., Miller C.A., Hundal J., Klco J.M., Challen G.A. Enforced differentiation of Dnmt3a-null bone marrow leads to failure with c-Kit mutations driving leukemic transformation. Blood 2015, 125:619-628.
3. Chadeau-Hyam M., Vermeulen R.C., Hebels D.G., Castagné R., Campanella G., Portengen L., Kelly R.S., Bergdahl I.A., Melin B., Hallmans G., et al. Prediagnostic transcriptomic markers of Chronic lymphocytic leukemia reveal perturbations 10 years before diagnosis. Ann. Oncol. 2014, 25:1065-1072. EnviroGenoMarkers project consortium.
4. Challen G.A., Sun D., Jeong M., Luo M., Jelinek J., Berg J.S., Bock C., Vasanthakumar A., Gu H., Xi Y., et al. Dnmt3a is essential for hematopoietic stem cell differentiation. Nat. Genet. 2011, 44:23-31.
5. Challen G.A., Sun D., Mayle A., Jeong M., Luo M., Rodriguez B., Mallaney C., Celik H., Yang L., Xia Z., et al. Dnmt3a and Dnmt3b have overlapping and distinct functions in hematopoietic stem cells. Cell Stem Cell 2014, 15:350-364.
6. Chang Y.I., You X., Kong G., Ranheim E.A., Wang J., Du J., Liu Y., Zhou Y., Ryu M.J., Zhang J. Loss of Dnmt3a and endogenous Kras(G12D/+) cooperate to regulate hematopoietic stem and progenitor cell functions in leukemogenesis. Leukemia 2015, 29:1847-1856.
7. Chen S.S., Sherman M.H., Hertlein E., Johnson A.J., Teitell M.A., Byrd J.C., Plass C. Epigenetic alterations in a murine model for chronic lymphocytic leukemia. Cell Cycle 2009, 8:3663-3667.
8. Datta J., Majumder S., Bai S., Ghoshal K., Kutay H., Smith D.S., Crabb J.W., Jacob S.T. Physical and functional interaction of DNA methyltransferase 3A with Mbd3 and Brg1 in mouse lymphosarcoma cells. Cancer Res. 2005, 65:10891-10900.
9. Dunphy C.H. Gene expression profiling data in lymphoma and leukemia: review of the literature and extrapolation of pertinent clinical applications. Arch. Pathol. Lab. Med. 2006, 130:483-520.
10. Gao X.N., Yan F., Lin J., Gao L., Lu X.L., Wei S.C., Shen N., Pang J.X., Ning Q.Y., Komeno Y., et al. AML1/ETO cooperates with HIF1α to promote leukemogenesis through DNMT3a transactivation. Leukemia 2015, 29:1730-1740.
11. Guan Y., Kuo W.L., Stilwell J.L., Takano H., Lapuk A.V., Fridlyand J., Mao J.H., Yu M., Miller M.A., Santos J.L., et al. Amplification of PVT1 contributes to the pathophysiology of ovarian and breast cancer. Clin. Cancer Res. 2007, 13:5745-5755.
12. Haferlach T., Kohlmann A., Wieczorek L., Basso G., Kronnie G.T., Béné M.C., De Vos J., Hernández J.M., Hofmann W.K., Mills K.I., et al. Clinical utility of microarray-based gene expression profiling in the diagnosis and subclassification of leukemia: report from the International Microarray Innovations in Leukemia Study Group. J. Clin. Oncol. 2010, 28:2529-2537.
13. Haney S.L., Hlady R.A., Opavska J., Klinkebiel D., Pirruccello S.J., Dutta S., Datta K., Simpson M.A., Wu L., Opavsky R. Methylation-independent repression of Dnmt3b contributes to oncogenic activity of Dnmt3a in mouse MYC-induced T-cell lymphomagenesis. Oncogene 2015, 34:5436-5446.
14. Hirst M., Marra M.A. Next generation sequencing based approaches to epigenomics. Brief. Funct. Genomics 2010, 9:455-465.
15. Hlady R.A., Novakova S., Opavska J., Klinkebiel D., Peters S.L., Bies J., Hannah J., Iqbal J., Anderson K.M., Siebler H.M., et al. Loss of Dnmt3b function upregulates the tumor modifier Ment and accelerates mouse lymphomagenesis. J. Clin. Invest. 2012, 122:163-177.
16. Huppi K., Volfovsky N., Runfola T., Jones T.L., Mackiewicz M., Martin S.E., Mushinski J.F., Stephens R., Caplen N.J. The identification of microRNAs in a genomically unstable region of human chromosome 8q24. Mol. Cancer Res. 2008, 6:212-221.
17. Isoda A., Kaira K., Iwashina M., Oriuchi N., Tominaga H., Nagamori S., Kanai Y., Oyama T., Asao T., Matsumoto M., Sawamura M. Expression of L-type amino acid transporter 1 (LAT1) as a prognostic and therapeutic indicator in multiple myeloma. Cancer Sci. 2014, 105:1496-1502.
18. Jeong M., Sun D., Luo M., Huang Y., Challen G.A., Rodriguez B., Zhang X., Chavez L., Wang H., Hannah R., et al. Large conserved domains of low DNA methylation maintained by Dnmt3a. Nat. Genet. 2014, 46:17-23.
19. Kim S.J., Zhao H., Hardikar S., Singh A.K., Goodell M.A., Chen T. A DNMT3A mutation common in AML exhibits dominant-negative effects in murine ES cells. Blood 2013, 122:4086-4089.
20. Kulis M., Heath S., Bibikova M., Queirós A.C., Navarro A., Clot G., Martínez-Trillos A., Castellano G., Brun-Heath I., Pinyol M., et al. Epigenomic analysis detects widespread gene-body DNA hypomethylation in chronic lymphocytic leukemia. Nat. Genet. 2012, 44:1236-1242.
21. Mayle A., Yang L., Rodriguez B., Zhou T., Chang E., Curry C.V., Challen G.A., Li W., Wheeler D., Rebel V.I., Goodell M.A. Dnmt3a loss predisposes murine hematopoietic stem cells to malignant transformation. Blood 2015, 125:629-638.
22. Nganga V.K., Palmer V.L., Naushad H., Kassmeier M.D., Anderson D.K., Perry G.A., Schabla N.M., Swanson P.C. Accelerated progression of chronic lymphocytic leukemia in Eμ-TCL1 mice expressing catalytically inactive RAG1. Blood 2013, 121:3855-3866, S1-S16.
23. Nguyen S., Meletis K., Fu D., Jhaveri S., Jaenisch R. Ablation of de novo DNA methyltransferase Dnmt3a in the nervous system leads to neuromuscular defects and shortened lifespan. Dev. Dyn. 2007, 236:1663-1676.
24. Okano M., Bell D.W., Haber D.A., Li E. DNA methyltransferases Dnmt3a and Dnmt3b are essential for de novo methylation and mammalian development. Cell 1999, 99:247-257.
25. Palamarchuk A., Yan P.S., Zanesi N., Wang L., Rodrigues B., Murphy M., Balatti V., Bottoni A., Nazaryan N., Alder H., et al. Tcl1 protein functions as an inhibitor of de novo DNA methylation in B-cell chronic lymphocytic leukemia (CLL). Proc. Natl. Acad. Sci. USA 2012, 109:2555-2560.
26. Peters S.L., Hlady R.A., Opavska J., Klinkebiel D., Novakova S., Smith L.M., Lewis R.E., Karpf A.R., Simpson M.A., Wu L., Opavsky R. Essential role for Dnmt1 in the prevention and maintenance of MYC-induced T-cell lymphomas. Mol. Cell. Biol. 2013, 33:4321-4333.
27. Peters S.L., Hlady R.A., Opavska J., Klinkebiel D., Pirruccello S.J., Talmon G.A., Sharp J.G., Wu L., Jaenisch R., Simpson M.A., et al. Tumor suppressor functions of Dnmt3a and Dnmt3b in the prevention of malignant mouse lymphopoiesis. Leukemia 2014, 28:1138-1142.
28. Russler-Germain D.A., Spencer D.H., Young M.A., Lamprecht T.L., Miller C.A., Fulton R., Meyer M.R., Erdmann-Gilmore P., Townsend R.R., Wilson R.K., Ley T.J. The R882H DNMT3A mutation associated with AML dominantly inhibits wild-type DNMT3A by blocking its ability to form active tetramers. Cancer Cell 2014, 25:442-454.
29. Sandhu S.K., Fassan M., Volinia S., Lovat F., Balatti V., Pekarsky Y., Croce C.M. B-cell malignancies in microRNA Eμ-miR-17~92 transgenic mice. Proc. Natl. Acad. Sci. USA 2013, 110:18208-18213.
30. Schweikert E.M., Devarajan A., Witte I., Wilgenbus P., Amort J., Förstermann U., Shabazian A., Grijalva V., Shih D.M., Farias-Eisner R., et al. PON3 is upregulated in cancer tissues and protects against mitochondrial superoxide-mediated cell death. Cell Death Differ. 2012, 19:1549-1560.
31. Shukla V., Ma S., Hardy R.R., Joshi S.S., Lu R. A role for IRF4 in the development of CLL. Blood 2013, 122:2848-2855.
32. Wu H., Xu T., Feng H., Chen L., Li B., Yao B., Qin Z., Jin P., Conneely K.N. Detection of differentially methylated regions from whole-genome bisulfite sequencing data without replicates. Nucleic Acids Res. 2015, 43:e141.
33. Yang H., Bueso-Ramos C., DiNardo C., Estecio M.R., Davanlou M., Geng Q.R., Fang Z., Nguyen M., Pierce S., Wei Y., et al. Expression of PD-L1, PD-L2, PD-1 and CTLA4 in myelodysplastic syndromes is enhanced by treatment with hypomethylating agents. Leukemia 2014, 28:1280-1288.
34. Yang L., Rau R., Goodell M.A. DNMT3A in haematological malignancies. Nat. Rev. Cancer 2015, 15:152-165.